Based on hierarchical classification and logistic regression of early US and French COVID-19 clinical trials we show that despite the registration of a large number of trials, only a minority had characteristics usually associated with providing robust and relevant evidence.
Keywords: COVID-19; Clinical Trial; France; Hierarchical Classification; United States.